Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, School of Medicine, Stanford, CA 94305, USA; Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave (E4-220), Palo Alto, CA 94304, USA.
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, School of Medicine, Stanford, CA 94305, USA; Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave (E4-220), Palo Alto, CA 94304, USA.
Exp Neurol. 2020 Nov;333:113428. doi: 10.1016/j.expneurol.2020.113428. Epub 2020 Aug 1.
Chronic pain is one of the most challenging and debilitating symptoms to manage after traumatic brain injury (TBI), yet the underlying mechanisms remain elusive. The disruption of normal endogenous pain control mechanisms has been linked to several forms of chronic pain and may play a role in pain after TBI. We hypothesized therefore that dysfunctional descending noradrenergic and serotonergic pain control circuits may contribute to the loss of diffuse noxious inhibitory control (DNIC), a critical endogenous pain control mechanism, weeks to months after TBI. For these studies, the rat lateral fluid percussion model of mild TBI was used along with a DNIC paradigm involving a capsaicin-conditioning stimulus. We observed sustained failure of the DNIC response up to 180-days post injury. We confirmed, that descending α adrenoceptor-mediated noradrenergic signaling was critical for endogenous pain inhibition in uninjured rats. However, augmenting descending noradrenergic signaling using reboxetine, a selective noradrenaline reuptake inhibitor, failed to restore DNIC after TBI. Furthermore, blocking serotonin-mediated descending signaling using selective spinal serotonergic fiber depletion with 5, 7-dihydroxytryptamine was also unsuccessful at restoring endogenous pain modulation after TBI. Unexpectedly, increasing descending serotonergic signaling using the selective serotonin reuptake inhibitor escitalopram and the serotonin-norepinephrine reuptake inhibitor duloxetine restored the DNIC response in TBI rats at both 49- and 180- days post injury. Consistent with these observations, spinal serotonergic fiber depletion with 5, 7-dihydroxytryptamine eliminated the effects of escitalopram. Intact α adrenoceptor signaling, however, was not required for the serotonin-mediated restoration of DNIC after TBI. These results suggest that TBI causes maladaptation of descending nociceptive signaling mechanisms and changes in the function of both adrenergic and serotonergic circuits. Such changes could predispose those with TBI to chronic pain.
慢性疼痛是颅脑损伤(TBI)后最具挑战性和使人虚弱的症状之一,但潜在机制仍难以捉摸。正常内源性疼痛控制机制的破坏与几种形式的慢性疼痛有关,并且可能在 TBI 后疼痛中发挥作用。因此,我们假设功能失调的下行去甲肾上腺素能和 5-羟色胺能疼痛控制回路可能导致弥漫性伤害性抑制控制(DNIC)丧失,这是一种关键的内源性疼痛控制机制,在 TBI 后数周到数月内发生。对于这些研究,使用了大鼠外侧液体冲击模型的轻度 TBI 以及涉及辣椒素条件刺激的 DNIC 范式。我们观察到 DNIC 反应持续失败,直至损伤后 180 天。我们证实,在未受伤的大鼠中,下行α肾上腺素能介导的去甲肾上腺素能信号对于内源性疼痛抑制至关重要。然而,使用再摄取抑制剂瑞波西汀增强下行去甲肾上腺素能信号未能在 TBI 后恢复 DNIC。此外,使用 5,7-二羟基色胺选择性脊髓 5-羟色胺能纤维耗竭阻断 5-羟色胺介导的下行信号也未能在 TBI 后恢复内源性疼痛调制。出乎意料的是,使用选择性 5-羟色胺再摄取抑制剂依地普仑和 5-羟色胺-去甲肾上腺素再摄取抑制剂度洛西汀增加下行 5-羟色胺能信号恢复了 TBI 大鼠在 49 天和 180 天的 DNIC 反应。与这些观察结果一致,用 5,7-二羟基色胺进行脊髓 5-羟色胺能纤维耗竭消除了依地普仑的作用。然而,TBI 后 5-羟色胺介导的 DNIC 恢复不需要完整的α肾上腺素能信号。这些结果表明,TBI 导致下行伤害性信号转导机制的适应不良以及肾上腺素能和 5-羟色胺能回路的功能变化。这种变化可能使那些患有 TBI 的人易患慢性疼痛。